Scynexis (SCYX) Gains from Investment Securities (2013 - 2026)
Scynexis' (SCYX) quarterly Gains from Investment Securities came in at -$14.2 million in Q2 2026, down 553.37% on a YoY basis from $3.1 million in Q2 2025, and down 369.61% quarter-over-quarter from $5.2 million in Q1 2026.
Analysis
Scynexis (SCYX) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Gains from Investment Securities for 13 consecutive years, with -$14.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gains from Investment Securities fell 553.37% year-over-year to -$14.2 million; the trailing twelve-month figure through Jun 2026 stood at -$9.6 million (up 36.69% YoY), and the FY2025 full-year result was -$5.8 million, up 58.01% from the prior year.
- Gains from Investment Securities retreated to -$14.2 million in Q2 2026 per SCYX's latest filing, from $5.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $21.7 million in Q3 2022 and bottomed at -$14.2 million in Q2 2026.
- Historically, Gains from Investment Securities has averaged -$1.8 million across 5 years, with a median of -$3.1 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities plunged 671.54% in 2022, then surged 316.08% in 2023.
- Over 5 years, Gains from Investment Securities stood at -$9.1 million in 2022, then soared by 69.18% to -$2.8 million in 2023, then decreased by 14.71% to -$3.2 million in 2024, then surged by 59.53% to -$1.3 million in 2025, then tumbled by 988.62% to -$14.2 million in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$14.2 million, $5.2 million, and -$1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.15 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | 640,000.00 |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | -2.93 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Jun 30, 2024 | 5.80 Mn |
| Mar 31, 2024 | -9.61 Mn |
| Dec 31, 2023 | -2.80 Mn |
| Sep 30, 2023 | -7.50 Mn |
| Jun 30, 2023 | -8.21 Mn |
| Mar 31, 2023 | 21.67 Mn |
| Dec 31, 2022 | -9.09 Mn |
| Sep 30, 2022 | 21.70 Mn |
| Jun 30, 2022 | -9.70 Mn |
| Mar 31, 2022 | -10.03 Mn |
| Sep 30, 2021 | -18.81 Mn |
| Jun 30, 2021 | -15.30 Mn |